Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
Want to see BCAX full AI Analyst Report?
BCAX Stock Chart & Stats
$24.01
-$0.31(-1.97%)
At close: 4:00 PM EST
$24.01
-$0.31(-1.97%)
Day’s Range― - ―
52-Week Range$7.80 - $24.25
Previous CloseN/A
Volume80.52K
Average Volume (3M)583.63K
Market Cap
$1.42B
Enterprise Value$1.09B
Total Cash (Recent Filing)$414.80M
Total Debt (Recent Filing)$1.71M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding65,467,186
10 Day Avg. Volume567,310
30 Day Avg. Volume583,633
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)2.29
Price to Sales (P/S)0.00
P/FCF Ratio-8.59
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-7.23
Forecast
1Y Price Target
$29.33Price Target Upside22.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway And FundingAnalyst notes substantial cash reserves that are expected to fund pivotal and expansion studies, reducing the need for urgent financing ahead of key development milestones.
Clinical Advancement And Regulatory PathwayAnalyst highlights advancement of a high‑dose weekly regimen into Phase 3 with a planned interim analysis that could support an accelerated approval filing based on objective response outcomes.
Commercial Launch PreparednessAnalyst points to planned key commercial hires, including a Chief Commercial Officer, as evidence of building launch readiness to capture market opportunity if trials confirm efficacy.
Bears Say
Limitations Of Interim Analysis DesignAnalyst flags that the interim analysis will be performed on a subset with unblinding limited to the approval preparation team, which could limit the breadth of evidence available to regulators and investors.
Safety And Competitive RiskAnalyst raises concerns that higher dosing increased severe adverse events and that competing therapies could reach the market earlier, both of which could constrain physician adoption and market share.
Uncertainty In Maintenance Dosing And Regulatory AlignmentAnalyst notes the less‑frequent maintenance dose has not been finalized and ongoing regulator discussions create uncertainty around the late‑stage development plan and label expectations.
Bicara Therapeutics Inc. News
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $7.80 and its highest was $24.25 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $1.42B.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s upcoming earnings report date is May 19, 2026 which is in 15 days.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Mar 30, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of -$0.672 by -$0.008.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 65,467,186 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$0.68 in its last earnings report, missing expectations of -$0.672. Following the earnings report the stock price went up 3.647%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bicara Therapeutics Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.33 (22.17% Upside)
$29.33 (22.17% Upside)
Blogger Sentiment
Bullish
BCAX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.45%
12-Months-Change
Fundamentals
Return on Equity
-32.49%
Trailing 12-Months
Asset Growth
-7.01%
Trailing 12-Months
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
BCAX Company Deck
BCAX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory momentum: Breakthrough Therapy Designation, selection of a pivotal dose (1,500 mg weekly), robust Phase Ib durability and survival data (DOR ~21.7 months; OS ~21.3 months; DOR >3x vs pembro+chemotherapy), advancement into Phase III with an interim analysis mid-2027, and an oversubscribed financing that extends runway into H1 2029. Key risks discussed include rising operating expenses, reliance on interim analysis and regulatory alignment for accelerated approval, enrollment/execution risk for the pivotal and bridging studies, and clinical uncertainty in exploratory indications (e.g., colorectal cancer). On balance, the call emphasized de-risking milestones and readiness for next-phase development, while acknowledging operational and regulatory dependencies.View all BCAX earnings summariesBCAX Stock 12 Month Forecast
Average Price Target
$29.33
▲(22.17% Upside)
Technical Analysis
Arbutus Biopharma
―
Bicycle Therapeutics
―
Relay Therapeutics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
21.84% Insiders
13.36% Mutual Funds
5.27% Other Institutional Investors
51.84% Public Companies and
Individual Investors